C.H.-based drug firm Cempra launches Phase 3 trial
Chapel Hill, N.C. —
The Phase 3 trial is for its antibiotic called solithromycin. It will be tested on patients with community-acquired bacterial pneumonia.
"Physicians need safe, convenient and active antibiotics to treat CABP, a disease that is the number one cause of death due to infection," said Prabhavathi Fernandes, chief executive officer of Cempra. "Current therapy for moderate to moderately-severe CABP is a choice between combination therapy with intravenous antibiotics or oral administration of fluoroquinolone antibiotics. The former involves intravenous therapy, possibly requiring hospital admission and the latter has been associated with significant side effects, possibly including Clostridium difficile infection due to the class's broad activity spectrum."
Please Log In to add a comment.
Best of TechWire Insider
- Star Trek gets real: Durham startup delivers interactive holograms
- Every tech company needs to join 'Global Government Surveillance Reform' movement
- Durham entrepreneurs find ally in Charlotte medtech incubator
- GoGown deal shows power, necessity of networking for startups
- New GSK oncology consortium targets combination therapies
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution